Gilenya vs Ocrevus
Side-by-side cost comparison based on Medicare Part D data
Gilenya
Fingolimod
Manufactured by Novartis
Ocrevus
Ocrelizumab
Manufactured by Genentech/Roche
Gilenya costs 76% less per claim than Ocrevus ($5,738.00 vs $23,635.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Gilenya | Ocrevus |
|---|---|---|
| Avg Cost Per Claim | $5,738.00 | $23,635.00 |
| Total Medicare Spending | $1.4B | $3.5B |
| Total Beneficiaries | 22,000 | 62,000 |
| Total Claims | 248,000 | 148,000 |
| Annual Cost/Patient | $64,682.00 | $56,419.00 |
| Year-over-Year Change | -14.8% | +16.5% |
| Generic Available | No | Yes |
| Patent Expiration | Sep 22, 2027 | Jan 31, 2023 |
| Manufacturer | Novartis | Genentech/Roche |
| Condition | Multiple Sclerosis | Multiple Sclerosis |
| Generic Name | Fingolimod | Ocrelizumab |
Gilenya vs Ocrevus: What the Data Shows
Gilenya (Fingolimod) and Ocrevus (Ocrelizumab) are both used to treat multiple sclerosis. Based on Medicare Part D data, Gilenya costs $5,738.00 per claim, which is 76% less than Ocrevus at $23,635.00 per claim.
Medicare spent $1.4B on Gilenya and $3.5B on Ocrevus. In terms of patient reach, Ocrevus serves more beneficiaries (62,000 vs 22,000).
Year-over-year spending changed -14.8% for Gilenya and +16.5% for Ocrevus. Ocrevus saw significant spending growth, suggesting increased utilization or price increases.
Ocrevus has a generic available, while Gilenya remains brand-only until its patent expires Sep 22, 2027.
Frequently Asked Questions
Gilenya is cheaper at $5,738.00 per claim, compared to $23,635.00 for Ocrevus. That makes Gilenya about 76% less expensive per claim based on Medicare Part D data.
Yes, both Gilenya and Ocrevus are used to treat multiple sclerosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Ocrevus has a generic version (Ocrelizumab) available, which is typically much cheaper. Gilenya is currently brand-only, with patent expiring Sep 22, 2027.
Medicare Part D spent $1.4B on Gilenya covering 22,000 beneficiaries, and $3.5B on Ocrevus covering 62,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.